Longidase, vaginal and rectal suppositories 3000 me 20 pcs

The prolongation of the enzyme action is achieved by covalent binding of the enzyme to the physiologically active polymeric carrier (azoximer). Longidase® shows antifibrotic properties, weakens acute phase of inflammation, regulates (increases or decreases depending on initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases humoral immune response and resistance of the body to infection.

The pronounced antifibrotic properties of Longidase are provided by conjugation of hyaluronidase with the carrier, which significantly increases resistance of the enzyme to denaturing influences and to the action of inhibitors: the enzymatic activity of Longidase is maintained when heated to 37 °С for 20 days, while the native hyaluronidase in the same conditions loses its activity within a day.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix.

Glycosaminoglycans change their basic properties as a result of depolymerization (breaking the bond between C1 acetylglucosamine and C4 glucuronic or induronic acids): viscosity is reduced, the ability to bind water, metal ions is reduced, the permeability of tissue barriers is temporarily increased, fluid movement in the intercellular space is facilitated, the elasticity of connective tissue is increased, which is manifested in a reduction of tissue swelling, flattening of scars, increased joint movement, reduction of contractures and prevention of their formation, reduction of adhesions.

Biochemical, immunological, histological and electron-microscopic investigations prove that Longidase® does not damage the normal connective tissue, but causes destruction of the connective tissue altered in composition and structure in the area of fibrosis.

Longidaza® has no mutagenic, embryotoxic, teratogenic and carcinogenic effect.

The drug is well tolerated by patients, no local and general allergic reactions were noted.

The use of Longidase in therapeutic doses during or after surgical treatment does not cause deterioration of the course of postoperative period or progression of the infection; it does not slow down bone regeneration.

Indications

Tuberculosis Adults and teenagers over 12 years old in the form of monotherapy and as a part of complex therapy of diseases accompanied by hyperplasia of connective tissue, including against the background of inflammatory process:

• in urology: Chronic prostatitis, interstitial cystitis, urethral and ureteral strictures, Peyronie’s disease, initial stage of benign prostatic hyperplasia, prevention of scarring and strictures formation after surgical interventions on urethra, bladder, ureters;
• in gynecology: adhesions (prevention and treatment) in the pelvis in chronic inflammatory diseases of the internal genitalia, after gynecological manipulations, including artificial abortions, previously suffered surgical interventions on the pelvic organs; intrauterine synechias, tubal-peritoneal sterility, chronic endomiometritis;
• in dermatovenereology: limited scleroderma, prevention of fibrotic complications of sexually transmitted infections;
• in surgery: prevention and treatment of adhesions after surgical interventions on abdominal organs; long-term non-healing wounds;
• in pulmonology and phthisiology: pneumofibrosis, siderosis, tuberculosis (cavernous fibrosis, infiltrative, tuberculoma), interstitial pneumonia, fibrosing alveolitis, pleurisy;
• to increase the bioavailability of antibacterial therapy in urology, gynecology, dermatovenerology, surgery, pulmonology, etc.

.

Active ingredient

Bovgialuronidase azoximer

Composition

Composition per suppository:

The active ingredient:

Bovgialuronidase azoximer (Longidase®) – 3000 IU;

Auxiliary Ingredients:

cocoa butter – to obtain a suppository weight of 1.3 g.

.

How to take, the dosage

Rectally, 1 sup. Once a day after a bowel cleansing.

Vaginally, once daily (at night) 1 spp. is inserted into the vagina in a supine position.

Longidaza® suppositories 3000 ME are recommended for a course of 10 to 20 injections.

The regimen of administration is adjusted depending on the severity, stage and duration of the disease: Longidaza® is administered every other day or with 2-3 day intervals.

Recommended regimens and doses:

In urology: 1 supoon once a day for 10 injections, then every 2-3 days for 10 injections, for a total of 20 supoon doses;

In gynecology: rectally or vaginally 1 supoon. After 2 days – 10 instillations, then if necessary maintenance therapy is prescribed;

– in dermatovenerology: 1 supp. in 1-2 days – 10-15 injections;

– in surgery: 1 supp. in 2-3 days – 10 injections;

– in pulmonology and phthisiology: 1 supp. in 2-4 days – 10-20 injections.

If necessary it is recommended to repeat the course of Longidase® not earlier than in 3 months or long-term maintenance therapy – 1 supoon. Once every 5-7 days for 3-4 months.

Interaction

When using Longidase® in patients receiving high doses of salicylates, cortisone, ACTH, estrogens or antihistamines, the effectiveness of the enzyme hyaluronidase may be reduced.

When prescribing in combination with other drugs it is necessary to consider the possibility of increasing their absorption (bioavailability) and enhancing the systemic action.

.

Special Instructions

Discontinue use of Longidase® in case of an allergic reaction.

When used against the background of acute foci of infection to prevent the spread of infection, administer under the cover of antimicrobial agents.

Contraindications

• high individual sensitivity to drugs with hyaluronidase activity, Longidase®;
• malignant tumors;
• pregnancy (no clinical experience of use);
• children under 12 years of age (efficacy and safety have not been studied).

With caution (use no more than once a week): renal failure; history of pulmonary bleeding.

Side effects

Rarely – allergic reactions in case of hypersensitivity.

.